Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Patients with a chronic skin disease, eg, atopic dermatitis, need self-management skills to increase their quality of life. We explored patients' needs for self-management support from healthcare professionals and how these needs can be met in a dermatology setting. Interpretive description methodology was chosen for iterative data collection and analysis of qualitative interviews with patients with atopic dermatitis. Two mutually dependent themes were found to be supportive of patients' self-management. was fundamental to successful support. However, from healthcare professionals was also needed on the wide range of topics that could be covered in the consultation based on individual needs. Patients need self-management support in addition to what can be found with family, friends, or peers. It is crucial that the support is delivered with an appreciative approach by healthcare professionals with profound knowledge of atopic dermatitis. Equally important is guidance towards agenda-setting, a way to co-construct the consultation with a clear focus on the specific patient's needs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10921857 | PMC |
| http://dx.doi.org/10.1177/23743735241231696 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Investigating the Use of Melatonin in Children With Atopic Dermatitis: A Cross-Sectional Study.
Pediatr Dermatol
September 2025
Harvard Medical School, Boston, Massachusetts, USA.
Background/objectives: Children with atopic dermatitis (AD) frequently experience sleep disturbances. Melatonin, an over-the-counter supplement, is increasingly used in the general pediatric population; however, its prevalence and perceived effectiveness in children with AD remain unclear.
Methods: Caregivers of pediatric patients (ages 1-17 years) with physician-diagnosed AD completed surveys on melatonin use, Patient Oriented Eczema Measure (POEM), and age-appropriate sleep questionnaires.
Human YKL-40 antibody alleviates atopic dermatitis-like skin inflammation by inhibiting exosome secretion via the JAK3/STAT6 pathway.
Arch Pharm Res
September 2025
College of Pharmacy and Medical Research Center, Chungbuk National University, 194-21, Osongsaengmyeong 1-ro, Osong-eup, Cheongju-si, Chungcheongbuk-do, 28160, Republic of Korea.
Atopic dermatitis (AD) is an inflammatory skin disease that produces a variety of inflammatory cytokines and chemokines. Chitinase-3-like protein 1 (CHI3L1, YKL-40) significantly contributes to AD-associated inflammatory response and is highly expressed in patients with AD. Therefore, this study elucidated the effects and potential mechanisms of human YKL-40 antibody on AD-affected skin.
View Article and Find Full Text PDFAtopic Dermatitis on TikTok: A Cross-Sectional Analysis of Content Quality and SoC Representation.
J Cutan Med Surg
September 2025
FACET Dermatology, Toronto, ON, Canada.
Thunberg root extract inhibits atopic dermatitis-like skin symptoms.
Allergol Immunopathol (Madr)
September 2025
Inflamm-Aging Translational Research Center, Ajou University Medical Center, Suwon, Republic of Korea;
Thunberg is a perennial herbaceous plant of the genus that belongs to the Apiaceae family and is effective in improving inflammation, gout, and dizziness. However, the skin pruritus improvement effect and mechanism of action of Thunberg root extract (PJRE) have not yet been reported. We investigated the effects of PJRE on the regulation of pruritus and inflammatory responses in compound 48/80 (C48/80)-treated mice, phorbol 12-myristate 13-acetate (PMA)/A23187-induced human skin mast cells, and LPS-stimulated mouse macrophages.
View Article and Find Full Text PDFCardiovascular Comorbidities in Atopic Dermatitis: A Case Report on the Impact of Dupilumab on Skin and Heart Function.
Cureus
August 2025
Department of Dermatology, Poznan University of Medical Sciences, Poznan, POL.
Atopic dermatitis (AD) is a chronic inflammatory skin condition often complicated by cardiovascular comorbidities, impacting treatment options and outcomes. In this paper, we present a 41-year-old patient with severe AD, asthma, and chronic heart failure, who responded well to dupilumab, showing significant improvements in skin severity scores and heart function. This case underscores the effectiveness of dupilumab in managing AD alongside complex comorbidities.
View Article and Find Full Text PDF